Literature DB >> 7540264

Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis.

T Olsson1.   

Abstract

In both multiple sclerosis (MS) and experimental autoimmune encephalomyelitis, the regulation of the cytokine spectrum and production is likely to have a decisive influence on disease outcome. Studies of cytokines, however, are hampered by the autocrine or paracrine nature of cytokines. Studies of cellular production by messenger RNA detection or cellular secretion are therefore necessary. Collective data suggest that certain cytokines associated with the TH1 phenotype or lymphocytes, such as tumor necrosis factor alpha, lymphotoxin, interleukin-12, and interferon gamma, may promote disease, while cytokines produced by the TH2 subset, such as interleukin-10, may limit disease. In addition, transforming growth factor beta is a putative disease downregulator. Increased knowledge in this field will likely lead to improved therapy for MS patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540264     DOI: 10.1212/wnl.45.6_suppl_6.s11

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

1.  Cytokine flow cytometry differentiates the clinical status of multiple sclerosis (MS) patients.

Authors:  S Inogés; J Merino; E Bandrés; P De Castro; M L Subirá; A Sánchez-Ibarrola
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

2.  IL-5 induces proliferation and activation of microglia via an unknown receptor.

Authors:  S M Liva; J de Vellis
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

3.  Phytosterols ameliorate clinical manifestations and inflammation in experimental autoimmune encephalomyelitis.

Authors:  Michael Valerio; Hong-Biao Liu; Reid Heffner; Robert Zivadinov; Murali Ramanathan; Bianca Weinstock-Guttman; Atif B Awad
Journal:  Inflamm Res       Date:  2010-12-07       Impact factor: 4.575

4.  Bystander-mediated stimulation of proteolipid protein-specific regulatory T (Treg) cells confers protection against experimental autoimmune encephalomyelitis (EAE) via TGF-β.

Authors:  Sangmu Jun; Javier Ochoa-Repáraz; Dagmara Zlotkowska; Teri Hoyt; David W Pascual
Journal:  J Neuroimmunol       Date:  2012-03-13       Impact factor: 3.478

5.  Silencing IFN-γ binding/signaling in astrocytes versus microglia leads to opposite effects on central nervous system autoimmunity.

Authors:  Xiaoli Ding; Yaping Yan; Xing Li; Ke Li; Bogoljub Ciric; Jingxian Yang; Yuan Zhang; Shuai Wu; Hui Xu; Wanjun Chen; Amy E Lovett-Racke; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  J Immunol       Date:  2015-03-20       Impact factor: 5.422

6.  Impact of IL-21 Gene Polymorphisms (rs2055979) and the Levels of Serum IL-21 on the Risk of Multiple Sclerosis.

Authors:  A Ali Abdulla; T Abdulaali Abed; W Razzaq Abdul-Ameer
Journal:  Arch Razi Inst       Date:  2022-02-28

7.  Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk.

Authors:  Katarina Tengvall; Jesse Huang; Cecilia Hellström; Patrick Kammer; Martin Biström; Burcu Ayoglu; Izaura Lima Bomfim; Pernilla Stridh; Julia Butt; Nicole Brenner; Angelika Michel; Karin Lundberg; Leonid Padyukov; Ingrid E Lundberg; Elisabet Svenungsson; Ingemar Ernberg; Sigurgeir Olafsson; Alexander T Dilthey; Jan Hillert; Lars Alfredsson; Peter Sundström; Peter Nilsson; Tim Waterboer; Tomas Olsson; Ingrid Kockum
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-02       Impact factor: 11.205

8.  Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis.

Authors:  Ana Paula Kallaur; Edna Maria Vissoci Reiche; Sayonara Rangel Oliveira; Andrea Name Colado Simão; Wildea Lice de Carvalho Jennings Pereira; Daniela Frizon Alfieri; Tamires Flauzino; Caio de Meleck Proença; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

9.  Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial.

Authors:  Fereshteh Ashtari; Mohammad Reza Savoj
Journal:  J Res Med Sci       Date:  2011-04       Impact factor: 1.852

10.  Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial.

Authors:  Vahid Shaygannejad; Mohsen Janghorbani; Fereshteh Ashtari; Hamed Dehghan
Journal:  Mult Scler Int       Date:  2012-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.